Mepivacaïne Hci B. Braun

Mepivacaine Hydrochloride, the active ingredient in Mepivacaïne Hci B. Braun, is a local anesthetic presented as an injectable solution for epidural, intramuscular, and perineural use. It provides reversible loss of sensation for dental procedures and regional surgical anesthesia, and is commonly used in adult patients requiring short‑acting regional block.

GNH USA supplies Mepivacaïne Hci B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. Our distribution network ensures reliable delivery to surgical centres and dental clinics across multiple continents.

Mepivacaine Hydrochloride is employed for local anesthesia in various dental and surgical settings.

- Dental procedures: rapid onset anesthesia for tooth extractions and restorative work. - Minor oral surgery: enables pain‑free incision and tissue manipulation. - Regional surgical anesthesia: facilitates epidural or peripheral nerve block for orthopedic and abdominal procedures.

Adverse reactions to Mepivacaine Hydrochloride are generally related to its local anesthetic properties and formulation.

Common Side Effects: - Injection site pain: mild discomfort or burning at the site of administration. - Tingling or numbness: transient sensory changes in the treated area. - Hypotension: occasional drop in blood pressure, especially with large epidural doses. - Nausea: mild gastrointestinal upset. - Dizziness: brief feeling of light‑headedness.

Serious or Rare Side Effects: - Cardiovascular collapse: severe hypotension or arrhythmia requiring emergency care. - Central nervous system toxicity: seizures, loss of consciousness, or respiratory depression. - Allergic reaction: urticaria, bronchospasm, or anaphylaxis. - Methemoglobinemia: rare blood disorder causing cyanosis. - Persistent nerve injury: prolonged numbness or motor deficit.

When using Mepivacaine Hydrochloride, clinicians should observe specific safety measures to minimize risk. - Patient assessment: evaluate cardiac history, arrhythmias, and allergy to amide anesthetics. - Dose calculation: adjust dose for age, weight, and comorbidities, especially in elderly or hepatic impairment. - Monitoring: observe vital signs and neurological status during and after administration. - Contraindications: avoid use in patients with known hypersensitivity to mepivacaine or related compounds. - Drug interactions: be cautious with other sodium channel blockers and vasodilators. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mepivacaine Hydrochloride may interact with several drug classes, altering its efficacy or safety profile. Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): additive cardiotoxicity and increased risk of arrhythmias. - General anesthetics (e.g., halothane, sevoflurane): potentiation of central nervous system depression. - Beta‑adrenergic blockers (e.g., propranolol): may enhance hypotensive effects. Moderate Interactions (Monitor Closely): - Opioids (e.g., fentanyl, morphine): synergistic respiratory depression. - Vasodilators (e.g., nitroglycerin): may augment blood pressure lowering. - MAO inhibitors: possible prolonged anesthetic effect.